Ranitidine for the prevention of complications following endoscopic sclerotherapy for esophageal varices.
Thirty one patients with significant esophageal variceal bleed were allocated alternately to receive endoscopic sclerotherapy along with ranitidine 300 mg daily or endoscopic sclerotherapy alone till eradication of varices. The mean sclerotherapy sessions, time and volume of sclerosant required for obliteration of varices were similar for the two groups. The esophageal varices were eradicated in all the patients except three in sclerotherapy alone group. There was statistically significant reduction in frequency of post sclerotherapy mucosal ulcers (P < 0.05) after addition of ranitidine to sclerotherapy. Rebleeding was not only significantly reduced (P < 0.05) in the sclerotherapy with ranitidine group but was minor and did not even require blood transfusion. In sclerotherapy alone group rebleeding was controlled by surgery in two patients and one died due to massive bleeding. The results of this study suggest a beneficial role of ranitidine in reducing post sclerotherapy mucosal ulcers and rebleeding. This effect of ranitidine emphasises the role of acid-pepsin in pathogenesis of these ulcers and its associated morbidity.
Kumar
A
A
Command Hospital (SC) Pune.
Mehta
S R
SR
Joshi
V
V
Kasthuri
A S
AS
Narayanan
V A
VA
D000328:Adult; D004932:Esophageal and Gastric Varices / Q000517:prevention & control / Q000628:therapy*; D004945:Esophagoscopy; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D008297:Male; D011899:Ranitidine / Q000627:therapeutic use*; D012008:Recurrence; D012597:Sclerosing Solutions / Q000008:administration & dosage; D015911:Sclerotherapy / Q000009:adverse effects* / Q000379:methods; D014456:Ulcer / Q000517:prevention & control
D012597:Sclerosing Solutions; D011899:Ranitidine